Cohance Lifesciences Ltd.
NSE: COHANCE · Pharmaceuticals
Snapshot
Unlock Cohance Lifesciences Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Cohance Lifesciences Limited is a Hyderabad-based pharmaceutical entity specialising in contract development and manufacturing (CDMO) services, active pharmaceutical ingredients (APIs), and specialty chemicals. The company operates as a consolidated platform following the strategic merger and rebranding of Suven Pharmaceuticals Limited.
Business Model
The company generates revenue through a diversified portfolio of CDMO services, the production of complex APIs, and the supply of specialty chemicals to global pharmaceutical clients. Its model leverages integrated manufacturing capabilities to support the full lifecycle of drug development and commercialisation.
Management Commentary
Management is focused on integrating the combined entities to leverage synergies and expand the company's footprint in the global pharmaceutical value chain.
Growth Outlook
Growth is expected to be driven by the expansion of CDMO service offerings and the scaling of specialty chemical production capabilities. The company aims to capitalise on the increasing global demand for outsourced pharmaceutical manufacturing.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where any failure to meet quality standards could lead to product recalls or facility bans.
- Integration Risk. The successful realisation of synergies following the merger of Suven Pharmaceuticals and Cohance Lifesciences is critical to achieving projected financial performance.
- Supply Chain Volatility. Dependence on raw material imports and global logistics exposes the company to price fluctuations and potential supply chain disruptions.
- Competitive Pressure. The pharmaceutical CDMO sector is highly competitive, requiring continuous investment in R&D to maintain market share against global peers.
Start your research today
Unlock AI insights, financials, peers and live data on Cohance Lifesciences Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,142 Cr
TTM · consolidated
NET PROFIT
₹59 Cr
TTM · consolidated
EPS
₹2.78
TTM · consolidated
RETURN ON EQUITY
2.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
3.5%
TTM · consolidated
P/E
164.2x
Q1 FY27 · consolidated
EV/EBITDA
50.5x
Q1 FY27 · consolidated
EBITDA MARGIN
16.3%
TTM · consolidated
NET PROFIT MARGIN
-10.7%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Cohance Lifesciences Ltd.COHANCE | ₹17,468 Cr | 164.24 | 50.50 | 41.2% | 16.3% | 2.1% | 3.5% | -49.2% |
Shilpa Medicare LimitedSHILPAMED | ₹18,857 Cr | 63.10 | 40.08 | 27.9% | 28.9% | 12.0% | 14.2% | +14.5% |
Eris Lifesciences Ltd.ERIS | ₹18,314 Cr | 28.11 | 17.93 | 9.7% | 35.5% | 19.7% | 15.5% | -25.1% |
Onesource Specialty Pharma Ltd.ONESOURCE | ₹17,630 Cr | -362.69 | 53.51 | 27.2% | 22.8% | -0.8% | 0.9% | -18.2% |
AstraZenca Pharma India Ltd.ASTRAZEN | ₹17,360 Cr | 102.34 | 65.98 | 31.1% | 10.5% | 20.6% | 25.7% | -23.8% |
Alembic Pharmaceuticals Ltd.APLLTD | ₹15,886 Cr | 22.91 | 13.84 | 14.1% | 15.8% | 12.7% | 14.3% | -15.8% |
As of Q1 FY27
Financials
Cohance Lifesciences Ltd.
NSE: COHANCE · Pharmaceuticals
Snapshot
Unlock Cohance Lifesciences Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Cohance Lifesciences Limited is a Hyderabad-based pharmaceutical entity specialising in contract development and manufacturing (CDMO) services, active pharmaceutical ingredients (APIs), and specialty chemicals. The company operates as a consolidated platform following the strategic merger and rebranding of Suven Pharmaceuticals Limited.
Business Model
The company generates revenue through a diversified portfolio of CDMO services, the production of complex APIs, and the supply of specialty chemicals to global pharmaceutical clients. Its model leverages integrated manufacturing capabilities to support the full lifecycle of drug development and commercialisation.
Management Commentary
Management is focused on integrating the combined entities to leverage synergies and expand the company's footprint in the global pharmaceutical value chain.
Growth Outlook
Growth is expected to be driven by the expansion of CDMO service offerings and the scaling of specialty chemical production capabilities. The company aims to capitalise on the increasing global demand for outsourced pharmaceutical manufacturing.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where any failure to meet quality standards could lead to product recalls or facility bans.
- Integration Risk. The successful realisation of synergies following the merger of Suven Pharmaceuticals and Cohance Lifesciences is critical to achieving projected financial performance.
- Supply Chain Volatility. Dependence on raw material imports and global logistics exposes the company to price fluctuations and potential supply chain disruptions.
- Competitive Pressure. The pharmaceutical CDMO sector is highly competitive, requiring continuous investment in R&D to maintain market share against global peers.
Start your research today
Unlock AI insights, financials, peers and live data on Cohance Lifesciences Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,142 Cr
TTM · consolidated
NET PROFIT
₹59 Cr
TTM · consolidated
EPS
₹2.78
TTM · consolidated
RETURN ON EQUITY
2.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
3.5%
TTM · consolidated
P/E
164.2x
Q1 FY27 · consolidated
EV/EBITDA
50.5x
Q1 FY27 · consolidated
EBITDA MARGIN
16.3%
TTM · consolidated
NET PROFIT MARGIN
-10.7%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27